Takeda Payments Will Undermine Revenue Amid China NRDL Pressures

AnalystLowTarget

Not Invested

Community Contributor

Published

07 Aug 25

AnalystLowTarget's Fair Value

HK$51.97

49.3% overvalued

16 Aug

HK$77.60

85.0%

3.3%

85.0%

3.3%

You can edit this narrative until Aug 7 10:36 PM. Then, changes will post as Updates.

Author's Valuation

HK$51.9749.3% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

HK$51.97

49.3% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

34.03%

Biotech revenue growth rate

8.35%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.00%

Calculation

CN¥137.19m

Earnings '28

136.48x

PE Ratio '28

CN¥18.72b

Market Cap '28

CN¥18.72b

Market Cap '28

321.52m

No. shares '28

CN¥58.23

Share Price '28

CN¥58.23 Share Price '28

Discounted to 2025 @ 6.89% p.a.

CN¥47.68

Fair Value '25

CN¥47.68 Fair Value '25

Converted to HKD @ 1.0899 CNY/HKD Exchange Rate

HK$51.97

Fair Value '25